In particular, TGFβ ligands are upregulated in several tumor microenvironments to induce angiogenesis, EMT and compromise immune cell surveillance (Thomas and Massagué, 2005; Jung et al., 2017; Muppala et al., 2017). Here, TGFB1 is linked to neoplasm.